Therapy Detail

Therapy Name Aflibercept + Capecitabine
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Aflibercept Zaltrap AVE 0005|Eylea VEGF Antibody 10 VEGFR Inhibitor (Pan) 29 Zaltrap (aflibercept) is comprised of human IgG fused to the extracellular domains of VEGFR1 and VEGFR2, which binds VEGF to inhibit tumor angiogenesis and metastasis (NCI Drug Dictionary). Zaltrap (aflibercept) is FDA approved in patients with metastatic colorectal cancer (FDA.gov).
Capecitabine Xeloda R340 Chemotherapy - Antimetabolite 10 Xeloda (capecitabine) is an antimetabolite that when activated to 5-FU ultimately inhibits DNA synthesis and cell division (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT01661972 Phase Ib/II Aflibercept + Capecitabine Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer Completed